| Odonate Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
4.61M |
$7.23M |
$1.57 |
19 Nov 2021 |
Indirect |
| Odonate Therapeutics, Inc. |
Director, 10%+ Owner |
Common Stock |
446K |
$699K |
$1.57 |
19 Nov 2021 |
Direct |
| Rain Oncology Inc. |
Director |
Common Stock, par value $0.001 per share |
0 |
$0 |
$1.21 |
26 Jan 2024 |
Direct |
| Tango Therapeutics, Inc. |
Other* |
Stock Option (Right to Buy) |
65K |
|
|
03 Sep 2024 |
Direct |
| iTeos Therapeutics, Inc. |
Director |
Stock Option (Right to Buy) |
24.2K |
|
|
11 Jun 2024 |
Direct |
| Mirati Therapeutics, Inc. |
Director |
Common Stock |
0 |
|
$59.02 |
23 Jan 2024 |
Direct |
| Mirati Therapeutics, Inc. |
Director |
Option to Purchase Common Stock |
0 |
|
|
23 Jan 2024 |
Direct |
| Rain Oncology Inc. |
Director |
Stock Option (Right to Buy) |
0 |
|
|
26 Jan 2024 |
Direct |